Free Trial

Boston Scientific (BSX) Stock Price, News & Analysis

$84.22
+1.65 (+2.00%)
(As of 11:58 AM ET)

About Boston Scientific Stock (NYSE:BSX)

Key Stats

Today's Range
$83.41
$84.89
50-Day Range
$72.96
$83.84
52-Week Range
$48.35
$84.89
Volume
3.70 million shs
Average Volume
6.03 million shs
Market Capitalization
$123.56 billion
P/E Ratio
70.77
Dividend Yield
N/A
Price Target
$85.38
Consensus Rating
Moderate Buy

Company Overview

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 89th Percentile

Boston Scientific scored higher than 89% of companies evaluated by MarketBeat, and ranked 139th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Boston Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 18 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Boston Scientific has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Boston Scientific's stock forecast and price target.
  • Earnings Growth

    Earnings for Boston Scientific are expected to grow by 12.92% in the coming year, from $2.40 to $2.71 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Boston Scientific is 69.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.64.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Boston Scientific is 69.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 146.63.

  • Price to Earnings Growth Ratio

    Boston Scientific has a PEG Ratio of 2.75. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Boston Scientific has a P/B Ratio of 6.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Boston Scientific's valuation and earnings.
  • Percentage of Shares Shorted

    0.75% of the outstanding shares of Boston Scientific have been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 2.61%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Boston Scientific does not currently pay a dividend.

  • Dividend Growth

    Boston Scientific does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.75% of the outstanding shares of Boston Scientific have been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 2.61%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Boston Scientific has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for Boston Scientific this week, compared to 18 articles on an average week.
  • Search Interest

    Only 32 people have searched for BSX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 13 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,627,877.00 in company stock.

  • Percentage Held by Insiders

    Only 0.50% of the stock of Boston Scientific is held by insiders.

  • Percentage Held by Institutions

    89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Boston Scientific's insider trading history.
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Stock News Headlines

Tula, Russia - october 19, 2021: Boston Scientific displayed modern laptop on red background — Stock Editorial Photography
Boston Scientific: Why This MedTech Giant Isn’t Slowing Down
Boston Scientific Co (NYSE: BSX) is a global medical device manufacturer that’s seeing a strong influx of investors as shares grind to new all-time highs.
Medtronic stock price
Medtronic Stock: Growth On Rise of the Cardiovascular Machines (BSX)
Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases
Biden's Successor: The Radical Threat to YOUR Savings!
Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
Boston Scientific (BSX) Gets a Buy from Wells Fargo
See More Headlines

BSX Stock Analysis - Frequently Asked Questions

Boston Scientific's stock was trading at $57.81 at the beginning of 2024. Since then, BSX shares have increased by 42.8% and is now trading at $82.57.
View the best growth stocks for 2024 here
.

Boston Scientific Co. (NYSE:BSX) issued its earnings results on Wednesday, July, 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping the consensus estimate of $0.58 by $0.04. Boston Scientific's quarterly revenue was up 14.5% compared to the same quarter last year.
Read the conference call transcript
.

Boston Scientific subsidiaries include these companies: VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and more.

Boston Scientific's top institutional investors include Primecap Management Co. CA (2.59%), Massachusetts Financial Services Co. MA (2.17%), Bank of New York Mellon Corp (1.01%) and Legal & General Group Plc (0.95%). Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Jeffrey B Mirviss, John Bradley Sorenson, Edward J Ludwig, Edward J Ludwig, Wendy Carruthers, Jonathan Monson, Eric Francis Yves Thepaut, Vance R Brown, Nelda J Connors, Arthur C Butcher, Charles J Dockendorff, Ian T Meredith, Jodi Euerle Eddy, David S Wichmann, David A Pierce and Scott Olson.
View institutional ownership trends
.

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), Walt Disney (DIS) and Bank of America (BAC).

Company Calendar

Last Earnings
7/24/2024
Today
9/19/2024
Next Earnings (Estimated)
10/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
10113710
Employees
48,000
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$85.38
High Stock Price Target
$95.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+1.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.95
Research Coverage
21 Analysts

Profitability

Net Income
$1.59 billion
Pretax Margin
14.07%

Debt

Sales & Book Value

Annual Sales
$15.23 billion
Cash Flow
$2.94 per share
Book Value
$13.33 per share

Miscellaneous

Outstanding Shares
1,467,096,000
Free Float
1,459,761,000
Market Cap
$123.43 billion
Optionable
Optionable
Beta
0.79

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 8, 2024. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • Boston Scientific Co. has shown consistent revenue growth over the past few quarters, indicating a strong financial performance.
  • The company's recent quarterly earnings report exceeded analysts' expectations, showcasing solid profitability.
  • With a diverse product portfolio in interventional medical specialties, Boston Scientific Co. has a strong market presence and growth potential.
  • Positive analyst ratings and target price upgrades suggest confidence in the company's future performance and stock value.
  • Despite recent fluctuations, Boston Scientific Co.'s stock price has remained relatively stable, offering a potential entry point for investors.

Boston Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • Market competition in the medical devices sector is intense, which could impact Boston Scientific Co.'s market share and margins.
  • Regulatory challenges and changes in healthcare policies may pose risks to the company's operations and profitability.
  • Fluctuations in healthcare spending and reimbursement rates could affect Boston Scientific Co.'s revenue and growth prospects.
  • The company's debt-to-equity ratio is relatively high, which may raise concerns about its financial leverage and stability.
  • While the stock has shown stability, the current price-to-earnings ratio of Boston Scientific Co. is higher than industry averages, potentially indicating overvaluation.

This page (NYSE:BSX) was last updated on 9/19/2024 by MarketBeat.com Staff
From Our Partners